文献速递免疫规划卫生政策与健康促进

16-29岁人群接种新冠mRNA疫苗(Comirnaty)的获益-风险评估

Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 years.
PubMed 文献 · Vaccine · 2022-03-28

美国FDA对16-29岁各年龄和性别亚组接种新冠mRNA疫苗(Comirnaty)进行获益-风险评估,采用模拟研究和敏感性分析。模型显示所有场景下获益均大于风险,包括16-17岁男性高风险亚组;最差场景下该亚组预测可预防COVID-19病例13577例、住院127例、ICU 41例、死亡1例,而疫苗归因心肌炎/心包炎超额病例范围为98-196例、住院98-196例、死亡0例。

要点

  • 所有年龄和性别亚组中,疫苗接种的获益均大于风险。
  • 最差场景下16-17岁男性仍显示获益大于风险。
  • 该评估存在不确定性,大流行演变可能改变获益与风险。

核心结论

  • 模型结果显示,在所有分析场景下,包括16-17岁男性高风险亚组,疫苗接种的获益均大于风险。

研究设计与样本

  • 美国FDA开展的模拟研究,对16-17、18-24、25-29岁年龄和性别(男/女)亚组进行获益-风险评估,并针对可能的大流行场景进行敏感性分析。

主要发现

  • 最差场景采用2021年7月10日美国COVID-19发病率(病例47-98/百万/天,住院1-4/百万/天)、疫苗针对COVID-19病例效力70%和针对住院效力80%,以及不太可能、悲观、非零的疫苗归因心肌炎死亡率。
  • 16-17岁男性最差场景下,模型预测可预防COVID-19病例13577例、住院127例、ICU 41例、死亡1例。
  • 16-17岁男性最差场景下,疫苗归因心肌炎/心包炎超额病例范围为98-196例、住院98-196例、死亡0例。

局限性

  • 该评估存在不确定性,因为疫苗接种的获益和风险可能随着大流行的持续演变而变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since authorization of the Pfizer-BioNTech COVID-19 Vaccine, mRNA (Comirnaty), real-world evidence has indicated the vaccines are effective in preventing COVID-19 cases and related hospitalizations and deaths. However, increased cases of myocarditis/pericarditis have been reported in the United States associated with vaccination, particularly in adolescents and young adults. FDA conducted a benefit-risk assessment to determine whether the benefits of vaccination outweigh the risks among various age (16-17, 18-24, 25-29) and sex (M/F) subgroups being considered for approved use of the vaccine. We conducted a simulation study with sensitivity analysis of the benefits and risks of the vaccine across possible pandemic scenarios. The model results show benefits outweigh the risks for all scenarios including the high-risk subgroup, males 16-17 years old. Our worst-case scenario used sex and age subgroup-specific incidences for COVID-19 cases (47-98 per million per day) and hospitalizations (1-4 per million per day) which are the US COVID-19 incidences as of July 10, 2021, vaccine efficacy of 70% against COVID-19 cases and 80% against hospitalization, and unlikely, pessimistic, non-zero vaccine-attributable myocarditis death rate. For males 16-17 years old, the model predicts prevented COVID cases, hospitalizations, ICUs, and deaths of 13577, 127, 41, and 1, respectively; while the predicted ranges for excess myocarditis/pericarditis cases, hospitalizations, and deaths attributable to the vaccine are [98-196], [98-196], and 0, respectively, for the worst-case scenario. Considering the different clinical implications of hospitalization due to COVID-19 infection versus vaccine-attributable myocarditis/pericarditis cases, we determine the benefits still outweigh the risks even for this high-risk subgroup. Our results demonstrate that the benefits of the vaccine outweigh its risks for all age and sex subgroups we analyze in this study. Uncertainties exist in this assessment as both benefits and risks of vaccination may change with the continuing evolution of the pandemic.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Funk PR, Yogurtcu ON, Forshee RA, et al. Benefit-risk assessment of COVID-19 vaccine, mRNA (Comirnaty) for age 16-29 years. Vaccine. 2022. PMID: 35370016. doi:10.1016/j.vaccine.2022.03.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。